Trench Rossi advises on pharma IPO
Trench Rossi Watanabe has advised Brazilian pharmacy chain d1000 Varejo Farma on an initial public offering on the São Paulo stock exchange, B3, raising 400 million reais (US$80 million)
Trench Rossi Watanabe, one of the country’s leading law firms active in M&A and capital markets transactions, advised d1000 Varejo Farma Participações on its initial public offering, which debuted in B3’s Novo Mercado segment with the code DVMF3 and raised 400 million reais. d1000 is the retail unit of Profarma Distribuidora de Produtos Farmacêuticos and responsible for the operation of Drogasmil, Farmalife, Drogarias Tamoio and Drogaria Rosário.
XP Investimentos Corretora de Câmbio, Títulos e Valores Mobiliários, and BB – Banco de Investimentos acted as lead managers on the transaction
“This is a very significant IPO because it was carried out in a scenario of low economic activity due to the COVID-19 pandemic. In these more delicate moments, it is even more important to count on a team of professionals internationally recognised for their expertise and dedication,” said Daniel Facó, Corporate & Finance partner at Trench Rossi Watanabe.
Trench Rossi Watanabe (Baker McKenzie) advised d1000 Varejo Farma Participações S.A. with a team led by partner and head of Trench Rossi Watanabe’s transactional practice areas Daniel de Miranda Facó (pictured left), and Corporate partner Felipe K. Calil (pictured right), including associates Paula Senna Ganem, Marcelo Moura, Catherine Shirazi and Marie Grinberg.
Mattos Filho, Veiga Filho, Marrey Jr. e Quiroga advised XP Investimentos Corretora de Câmbio, Títulos e Valores Mobiliários S.A. and BB – Banco de Investimentos S.A. with partner Vanessa Fiusa, senior associate Ralff Barilli and associate Isabella Polatto Roque.
